138 related articles for article (PubMed ID: 34351819)
1. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
Krishnan M; Kasinath P; High R; Yu F; Teply BA
JCO Oncol Pract; 2022 Jan; 18(1):e175-e182. PubMed ID: 34351819
[TBL] [Abstract][Full Text] [Related]
2. Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE; Pasternak M; Dolter S; Grosjean HAI; Lim CA; Stukalin I; Goutam S; Navani V; Heng DYC; Cheung WY; Morris DG; Pabani A
JTO Clin Res Rep; 2023 Apr; 4(4):100482. PubMed ID: 37090101
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
4. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Baratam P; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Cancer; 2020 Mar; 126(6):1208-1216. PubMed ID: 31829450
[TBL] [Abstract][Full Text] [Related]
5. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings.
Kapoor A; Noronha V; Patil VM; Menon N; Joshi A; Abraham G; Prabhash K
Medicine (Baltimore); 2021 Apr; 100(13):e25115. PubMed ID: 33787593
[TBL] [Abstract][Full Text] [Related]
7. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Dudnik E; Kareff S; Moskovitz M; Kim C; Liu SV; Lobachov A; Gottfried T; Urban D; Zer A; Rotem O; Onn A; Wollner M; Bar J;
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597218
[TBL] [Abstract][Full Text] [Related]
8. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes.
Wells L; Cerniglia M; Hall S; Jost AC; Britt G
J Immunother Precis Oncol; 2022 May; 5(2):37-42. PubMed ID: 35664089
[TBL] [Abstract][Full Text] [Related]
10. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
[TBL] [Abstract][Full Text] [Related]
11. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Pan GQ; Zhang X; Mao XC; Tan SY; Li RZ; Wang DX; Dong ZR; Yan YC; Li T
Expert Rev Anticancer Ther; 2024 May; 24(5):303-312. PubMed ID: 38623811
[TBL] [Abstract][Full Text] [Related]
13. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.
Neeman E; Gresham G; Ovasapians N; Hendifar A; Tuli R; Figlin R; Shinde A
Oncologist; 2019 Dec; 24(12):e1460-e1466. PubMed ID: 31227648
[TBL] [Abstract][Full Text] [Related]
14. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
15. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
[TBL] [Abstract][Full Text] [Related]
16. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Diker O; Olgun P; Balyemez U; Sigit Ikiz S
Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
19. Administration of Immune Checkpoint Inhibitors Near the End of Life.
Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
[TBL] [Abstract][Full Text] [Related]
20. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
